Ultimele actualizari :
19/11/2024
Citostatic   Ipilimumab  
Injectabil
Stabilitatea in solutie Stabilitatea in amestec Factorii care influenteaza stabilitatea Compatibilitate Microunde Bibliografie pdf

Denumirea comerciala   Denumirea comerciala     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers

Yervoy Argentina, Australia, Belgia, Canada, Chilli, Columbia, Danemarca, Elvetia, Franta, Germania, Irlanda, Islanda, Italia, Marea Britanie, Mexic, Norvegia, Polonia, Portugalia, Romania, Slovenia, Spania, SUA, Suedia, Turcia
Bibliografie   Injectabil   Bibliografie : Ipilimumab  
tip publicare
2296 Laborator Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017
3352 Laborator Ipilimumab (Yervoy®) - Summary of Product Characteristics
Bristol Myers Squibb 2011
3446 poster Bardo P, Vieillard V, Astier A, Paul M.
Stabilité physicochimique de solutions diluées d'ipilimumab : résultats préliminaires à 1 mois.
SFPO Congress, Mandelieu, France 2013
3850 ziar Bardo-Brouard P, Vieillard V, Shekarian T, Marabelle A, Astier A, Paul M.
Stability of ipilimumab in its original vial after opening allows its use for at least 4 weeks and facilitates pooling of residues.
Eur J Cancer 2016 ; 58: 8-16.

  Mentions Légales